Loading...
Loading...
Dr. Reddy's Laboratories
RDY announced today that Azacitidine
for Injection 100 mg/vial, a bioequivalent generic version of VIDAZA®
(azacitidine for injection), is approved by the United States Food
& Drug Administration (USFDA) on September 16, 2013. The launch of
product in the market is planned in the near-term.
The VIDAZA® brand had U.S. sales of approximately $378.5
Million for the most recent twelve months ending July 2013 according to
IMS Health.
Dr. Reddy's Azacitidine for Injection 100 mg/vial is available in
single-use vials.
Disclaimer
This press release includes forward-looking statements, as defined in
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in